Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: The ProBONE II study

Osteoporosis International

Volumn 25, Issue 4, 2014, Pages 1369-1378

  Hadji, P ^a   Kauka, A ^a   Ziller, M ^a   Birkholz, K ^b   Baier, M ^b   Muth, M ^b   Bauer, M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Adjuvant; Bisphosphonate; Bone mineral density; Bone turnover markers; Breast cancer; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PLACEBO; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT; ESTROGEN RECEPTOR; IMIDAZOLE DERIVATIVE; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER TREATMENT INDUCED BONE LOSS; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HORMONAL THERAPY; HORMONE RECEPTOR POSITIVE BREAST CANCER; HOT FLUSH; HUMAN; JAW OSTEONECROSIS; LUMBAR SPINE; LYMPHEDEMA; MENOPAUSAL SYNDROME; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; OSSIFICATION; OSTEOLYSIS; PARESTHESIA; PREMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SLEEP DISORDER; TOOTH EXTRACTION; YOUNG ADULT; BONE REMODELING; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMUR; LUMBAR VERTEBRA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FEMUR; HUMANS; IMIDAZOLES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897023705     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2615-z     Document Type: Article

References (35)

1. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308-310 (Pubitemid 20058296)
2. Fuleihan GE, Testa MA, Angell JE, Porrino N, Leboff MS (1995) Reproducibility of DXA absorptiometry: a model for bone loss estimates. J Bone Miner Res 10:1004-1014
3. Jordan VC, Fritz NF, Tormey DC (1987) Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on nodepositive patients with breast cancer. Cancer Res 47:624-630 (Pubitemid 17009636)
4. Lower EE, Blau R, Gazder P, Tummala R (1999) The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 8:949-954 (Pubitemid 29501939)
5. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729 (Pubitemid 26134232)
6. Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J, Sidlofsky S, Trudeau M, Hood N, Redwood S (1999) Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17:120-129 (Pubitemid 29022385)
7. Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311 (Pubitemid 32642182)
8. Fuleihan Gel H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90:3209-3214 (Pubitemid 41014277)
9. Hadji P, Ziller M, Maskow C, Albert U, Kalder M (2009) The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer 45:3205-3212
10. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlbock M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849
11. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS (2005) Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558 (Pubitemid 40344388)
12. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299-1309
13. Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A, Aapro MS (2012) Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev 38:798-806
14. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(Suppl 1):S3-S18
15. Lipton A, Costa L, Ali SM, Demers LM (2001) Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181-185 (Pubitemid 32452019)
16. Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E (2010) Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 95:559-566
17. Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546-2555
18. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26:4739-4745
19. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E (2011) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 47:683-689
20. Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453-475
21. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398-405
22. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829-836 (Pubitemid 350002883)
23. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405
24. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE Jr, Swain SM, Costantino JP, Mamounas EP, Wolmark N (2012) Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734-742
25. Möbus V, Diel IJ, Elling D, Harbeck N, Jackisch C, Thomssen C, Untch M, Conrad B, Schneeweiss A, Kreienberg R, Huober J, Müller V, Lück HJ, Bauerfeind I, Loibl S, Nekljudova V, von Minckwitz G (2011) GAIN study: a phase III trial to compare ETC. vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim efficacy analysis. Presented at: CTRCAACR San Antonio Breast Cancer Symposium; 6-10 December 2011; San Antonio, TX. Abstract S2-4.
26. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic- Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
27. Chlebowski RT, Col N (2012) Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem 12:144-150
28. Chlebowski RT, Col N (2011) Bisphosphonates and breast cancer incidence and recurrence. Breast Dis 33:93-101
29. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
30. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347 (Pubitemid 27167365)
31. Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708 (Pubitemid 28222145)
32. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA (2009) Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27:1047-1053
33. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky PC, Jakesz R, Singer CF, Eidtmann H, Fesl C, Eiermann W, Greil R (2011) Significantly improved overall survival with adjuvant zoledronic acid in premenopausal breast cancer patients with endocrine-receptor- positive early breast cancer. Presented at: CTRC-AACR San Antonio Breast Cancer Symposium; 6- 10 December 2011; San Antonio, TX. Abstract S1-2.
34. Marshall H, Gregory W, Bell R, Cameron DA, Dodwell DJ, Keane MM, Gil MJ, Davies C, Coleman RE (2012) Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): the influence of menopausal status and age on treatment effects. J Clin Oncol 30(Suppl): Abstract 502.
35. Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, Gregory WM, Cameron D, Bell R. (2012) Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Presented at: CTRCAACR San Antonio Breast Cancer Symposium; 4 -8 December 2012; San Antonio, TX. Abstract S6-4.